ES2196056T3 - Sustitutos para dianas y paneles de referencia mejorados. - Google Patents

Sustitutos para dianas y paneles de referencia mejorados.

Info

Publication number
ES2196056T3
ES2196056T3 ES95906754T ES95906754T ES2196056T3 ES 2196056 T3 ES2196056 T3 ES 2196056T3 ES 95906754 T ES95906754 T ES 95906754T ES 95906754 T ES95906754 T ES 95906754T ES 2196056 T3 ES2196056 T3 ES 2196056T3
Authority
ES
Spain
Prior art keywords
reactivity
panels
receptor
panel
members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95906754T
Other languages
English (en)
Inventor
Lawrence M Kauvar
Hugo O Villar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/177,673 external-priority patent/US5587293A/en
Application filed by Telik Inc filed Critical Telik Inc
Application granted granted Critical
Publication of ES2196056T3 publication Critical patent/ES2196056T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Laminated Bodies (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

SE PRESENTA UN METODO PARA DETERMINAR LA REACTIVIDAD DE UN COMPUESTO CANDIDATO, CON UN ELEMENTO OBJETIVO CUYO METODO NO REQUIERE LA PRESENCIA FISICA DEL ELEMENTO OBJETIVO. MEDIANTE LA ELABORACION DE UNA FORMULA PARA TRATAR LOS DATOS OBTENIDOS DE UN JUEGO DE REFERENCIAS DE SUSTITUTIVOS DEL ELEMENTO OBJETIVO CUYA FORMULA PUEDE PREDECIR LA REACTIVIDAD CON EL ELEMENTO OBJETIVO, EL COMPUESTO QUE QUIERE ENSAYARSE PUEDE VALORARSE FISICAMENTE CON RESPECTO A LOS PANELES DE REFERENCIA, A LA FORMULA APLICADA, Y PUEDE PREDECIRSE LA REACTIVIDAD CON EL ELEMENTO OBJETIVO REAL. SE DESCRIBEN LOS PANELES COMPUESTOS POR MIEMBROS INDIVIDUALES, ESTANDO COMPUESTOS LOS CITADOS MIEMBROS POR PROTEINAS, EN DONDE AL MENOS UNO DE LOS MIEMBROS DEL PANEL ES UNA PROTEINA QUE NO ES UNA INMUNOGLOBINA (IG) O UN FRAGMENTO DE ELLA Y EN DONDE LA PRESENCIA DE LA CITADA PROTEINA NO IG ENRIQUECE EL PANEL. ESTOS PANELES PUEDEN ENSAYARSE EN CUANTO A SU REACTIVIDAD CON UNA SUSTANCIA ANALITICA PARA CREAR UN PERFIL. ESTOS PERFILES PUEDEN USARSE EN LA ADAPTACION DE PATRONES, EL ANALISIS DE MUESTRAS Y OTROS ANALISIS.
ES95906754T 1994-01-06 1995-01-05 Sustitutos para dianas y paneles de referencia mejorados. Expired - Lifetime ES2196056T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/177,673 US5587293A (en) 1994-01-06 1994-01-06 Method to identify binding partners
US08/308,813 US5798275A (en) 1994-01-06 1994-09-19 Profiling reference panel enriched by non-IG proteins

Publications (1)

Publication Number Publication Date
ES2196056T3 true ES2196056T3 (es) 2003-12-16

Family

ID=26873529

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95906754T Expired - Lifetime ES2196056T3 (es) 1994-01-06 1995-01-05 Sustitutos para dianas y paneles de referencia mejorados.
ES02009879T Expired - Lifetime ES2284743T3 (es) 1994-01-06 1995-01-05 Sustitutos para dianas y paneles de referencia mejorados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02009879T Expired - Lifetime ES2284743T3 (es) 1994-01-06 1995-01-05 Sustitutos para dianas y paneles de referencia mejorados.

Country Status (11)

Country Link
US (1) US5741653A (es)
EP (1) EP0738390B1 (es)
JP (1) JPH09507300A (es)
AT (2) ATE236401T1 (es)
AU (1) AU700497B2 (es)
CA (1) CA2178096C (es)
DE (2) DE69535463T2 (es)
DK (2) DK0738390T3 (es)
ES (2) ES2196056T3 (es)
PT (1) PT738390E (es)
WO (1) WO1995018969A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0879282T3 (da) 1996-01-17 2003-10-20 Imp College Innovations Ltd Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)
US6054286A (en) * 1996-06-18 2000-04-25 Telik, Inc. Methods to identify immunomodulators using cognate interaction of PKC-theta
AU5902098A (en) * 1997-01-03 1998-07-31 Terrapin Technologies, Inc. Method to classify gene products
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
DK1030678T3 (da) 1997-11-12 2006-12-11 Johnson & Johnson Pharm Res Fremgangsmåde med höj kapacitet til funktionel klassificering af proteiner der identificeres under anvendelse af en genomikfremgangsmåde
EP1049796A1 (en) * 1997-12-18 2000-11-08 Sepracor, Inc. Methods for the simultaneous identification of novel biological targets and lead structures for drug development
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6625547B1 (en) 1998-08-05 2003-09-23 Washington State University Research Foundation Relative rates of cytochrome p450 metabolism
CA2339581A1 (en) * 1998-08-05 2000-02-17 University Of Pittsburgh Modelling organic compound reactivity in cytochrome p450 mediated reactions
US20040224338A1 (en) * 1998-08-12 2004-11-11 Zycos Inc., A Delaware Corporation Profiling and cataloging expressed protein tags
DE69933679T2 (de) * 1998-08-12 2007-08-23 Zycos Inc., Cambridge Darstellung des profils und katalogisierung von exprimierten proteinmarkern
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6569631B1 (en) 1998-11-12 2003-05-27 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6875575B1 (en) 1998-11-25 2005-04-05 Osi Pharmaceuticals, Inc. Diagnostic methods for neoplasia
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
EP3712897A1 (en) * 2019-03-22 2020-09-23 Tata Consultancy Services Limited Automated prediction of biological response of chemical compounds based on chemical information

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300425A (en) * 1987-10-13 1994-04-05 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US5338659A (en) * 1991-04-02 1994-08-16 Terrapin Technologies, Inc. Method for determining analyte concentration by cross-reactivity profiling
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US4963263A (en) * 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5217869A (en) * 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
WO1989003430A1 (en) * 1987-10-13 1989-04-20 Terrapin Diagnostics, Ltd. Method to produce immunodiagnostic reagents
US5340474A (en) * 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
EP0557276A1 (en) * 1989-12-29 1993-09-01 University Technologies International Inc. (Uti) Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
WO1992008471A1 (en) * 1990-11-09 1992-05-29 Verigen, Inc. Method for determining the sensitivity and/or specificity of an assay system for detecting antibodies

Also Published As

Publication number Publication date
US5741653A (en) 1998-04-21
EP0738390A1 (en) 1996-10-23
ES2284743T3 (es) 2007-11-16
DE69535463T2 (de) 2008-01-03
CA2178096A1 (en) 1995-07-13
DE69530179T2 (de) 2004-04-08
DK1235072T3 (da) 2007-07-16
ATE236401T1 (de) 2003-04-15
CA2178096C (en) 2004-03-09
JPH09507300A (ja) 1997-07-22
AU700497B2 (en) 1999-01-07
EP0738390B1 (en) 2003-04-02
DE69530179D1 (de) 2003-05-08
WO1995018969A1 (en) 1995-07-13
DE69535463D1 (de) 2007-05-24
PT738390E (pt) 2003-07-31
DK0738390T3 (da) 2003-07-21
ATE359509T1 (de) 2007-05-15
AU1522195A (en) 1995-08-01

Similar Documents

Publication Publication Date Title
ES2196056T3 (es) Sustitutos para dianas y paneles de referencia mejorados.
Hollung et al. Application of proteomics to understand the molecular mechanisms behind meat quality
BR9106217A (pt) Processo para a analise de uma amostra de gas,disposicao de analise,empregos disto e instalacao de teste com a citada disposicao
DK0933082T3 (da) Fremgangsmåde til manipulation af celledifferentiering
BR9508417A (pt) Acido nucléico isolado cdna isolado proteina isolada vetor de expressão processo para detectar câncer e pré-câncer de pulmão processo para selecionar especimes humanas para proteina hcaviii processo para testar amostra de célula humana anticorpo e composição terapêutica
BRPI0308585B8 (pt) anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
PT914344E (pt) Ensaio e reagentes para a quantificacao de hbnp
ATE461450T1 (de) Verwendung von kontrollflächen zur detektion von störproben in einem nachweisverfahren
BR9809778A (pt) Polinucleotìdeo isolado, vetor de expressão, peptìdeo ou polipetìdeo isolado, anticorpo, processo para produzir o mesmo, fragmentos de anticorpos, anticorpos de cadeia única ou anticorpos humanizados, e, anticorpo anti-idiotìpico.
Righetti et al. The proteome: anno Domini 2002
Segura et al. Procedures for monitoring recombinant erythropoietin and analogues in doping control
DK1117685T3 (da) Behandling af inflammatorisk sygdom
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
DK26587A (da) Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
HK1021229A1 (en) A in vitro method of determining the presence of aprotein in an isolated biological sample.
SE0003566D0 (sv) A method for the quantitative determination of one or more compounds
DK0789844T3 (da) Anvendelse af et BMP-proteinreceptor-kompleks til screening for aktive stoffer i knoglemetabolisme og celler, der er cotransficieret med en type II-BMP-receptor og en type I-BMP-receptor
PT98073A (pt) Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 beta por metodos recombinantes e de composicoes farmaceuticas que os contem
DE69007155D1 (de) Automatisierte Schnittentwicklungsanalyse von mehrfachen Proben.
DK162726C (da) Fremgangsmaade til eliminering af falsk positive resultater ved bestemmelse af atl virus-antistof og reagens dertil
Springer et al. Characterization of plasma membrane proteins from ovarian cancer cells using mass spectrometry
Dunn Quantitative amino acid analysis
Krogh-Meibom et al. A time-resolved immunofluorometric assay for quantification of collectin-43
ATE249047T1 (de) Verfahren zum spezifischen nachweis von glykosilierten proteinen